Valeant’s new CEO needs to keep staff, sell assets and pay down the company’s $30 billion of debt, all while coping with drug pricing pressures says Thomson Reuters Breakingviews.
Valeant’s new CEO needs to keep staff, sell assets and pay down the company’s $30 billion of debt, all while coping with drug pricing pressures says Thomson Reuters Breakingviews.